Search Results - Catherine Balint
- Showing 1 - 3 results of 3
-
1
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Meta... by Pravin T. P. Kaumaya, Kevin Foy, Joan T. Garrett, Sharad Rawale, Daniele Vicari, Jennifer M. Thurmond, Tammy Lamb, Aruna Mani, Y Kane, Catherine Balint, Donald Chalupa, Gregory A. Otterson, Charles L. Shapiro, Jeffrey M. Fowler, Michael R. Grever, Tanios Bekaii‐Saab, William E. Carson
Published 2009Artigo -
2
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers by Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li, Motoyasu Saji, Laura W. Goff, John Kauh, Bert H. O’Neil, Stephanie Balsom, Catherine Balint, R. Liersemann, Vasily Vasko, Mark Bloomston, W. Marsh, L. Austin Doyle, Gilian Ellison, Michael R. Grever, Matthew D. Ringel, Miguel A. Villalona‐Calero
Published 2011Artigo -
3
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas by Tanios Bekaii‐Saab, Joseph Markowitz, Nichole Prescott, Wolfgang Sadée, Nyla A. Heerema, Lai Wei, Zunyan Dai, Audrey C. Papp, Angela Campbell, Kristy Culler, Catherine Balint, Bert H. O’Neil, Ruey-min Lee, Mark M. Zalupski, Janet Dancey, Helen Chen, Michael R. Grever, Charis Eng, Miguel A. Villalona‐Calero
Published 2009Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Cancer
Gastroenterology
Oncology
Adjuvant
Adverse effect
Antibody
Biochemistry
Biology
Breast cancer
Cell biology
Chemistry
Clinical endpoint
Clinical trial
Colorectal cancer
Epitope
Gene
Hepatocellular carcinoma
Immune system
Immunogenicity
Immunology
Immunotherapy
KRAS
Kinase
Lapatinib
MAPK/ERK pathway
MEK inhibitor
Mutation
Rash